Onconetix (ONCO) Operating Expenses (2021 - 2026)

Onconetix (ONCO) has reported Operating Expenses for 6 consecutive years, with $2.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses rose 36.35% year-over-year to $2.7 million in Q2 2026; TTM through Jun 2026 was $16.8 million, a 64.34% decrease from a year earlier, with the FY2025 full-year figure at $18.5 million, down 67.87% from the prior year.
• Operating Expenses was $2.7 million for Q2 2026 at Onconetix, down from $10.2 million in the prior quarter.
• Over five years, Operating Expenses peaked at $29.8 million in Q4 2024 and troughed at $1.5 million in Q4 2025.
• A 5-year average of $7.6 million and a median of $4.1 million in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses jumped 544.54% in 2023 and sank 94.87% in 2025, its largest moves.
• Over 5 years, Operating Expenses stood at $3.2 million in 2022, then jumped by 544.54% to $20.9 million in 2023, then jumped by 42.47% to $29.8 million in 2024, then slumped by 94.87% to $1.5 million in 2025, then soared by 78.88% to $2.7 million in 2026.
• The last three Operating Expenses figures came in at $2.7 million (Q2 2026), $10.2 million (Q1 2026), and $1.5 million (Q4 2025), per Business Quant data.